|
Author | Agent | Study design | Number of patients | Prior ASCT | Response | Median duration of response | Toxicity |
|
Younes et al. [18] | Brentuximab vedotin | II | 102 | 102 70% PRD | ORR 75% CR 34% PR 40% | PFS 5.6 months OS 22.4 months | PSN, fatigue, nausea, neutropenia, diarrhoea, and pyrexia |
|
Younes et al. [22] | Rituximab | N/A | 22 | NR | ORR 22% CR 1, PR 4 | 8.7 months | NR |
|
Oki et al. [23] | Rituximab + gemcitabine | II | 33 | 55% | ORR 48% CR 5, PR 11 | FFS 2.7 months | Gr 3-4 neutropenia and thrombocytopenia |
|
O’Mahony et al. [24] | Daclizumab | II | 30 | NR | CR 12, PR 7, SD 5 | N/A | Thrombocytopenia |
|
Little et al. [25] | Vinblastine | N/A | 17 | 17 | ORR 59% CR 12% PR 47% | OS 38.8 months | Fever and neutropenia |
|
Devizzi et al. [26] | Vinorelbine | N/A | 24 | NR | ORR 45% | N/A | N/A |
|
Venkatesh et al. [27] | Gemcitabine | II | 27 | 18 | PR 22% SD 52% | 6.4 months | Gr 3 thrombocytopenia, neutropenia, and anemia |
|
Spencer et al. [28] | Vinorelbine + gemcitabine | II | 8 | 8 | ORR 75% | N/A | N/A |
|
Bartlett et al. [29] | Gemcitabine + vinorelbine + pegylated liposomal doxorubicin | II | 91 | 40 | ORR 75% RR in prior ASCT Pts 70% | 8.5 months in prior ASCT | Gr 3-4 thrombocytopenia neutropenia, and mucositis |
|
de Filippi et al. [30] | Bendamustine | II | 34 | 75% | ORR 56% CR 33% PR 19% | 5 months | Gr 3-4 thrombocytopenia, anemia, and infections |
|
Mendle et al. [34] | Bortezomib + gemcitabine | II | 18 | NR | ORR 22% | NR | Gr 3 elevation of transaminase enzyme |
|
Kirschbaum et al. [35] | Vorinostat | II | 25 | NR | ORR 4% | PFS 4.8 months | Gr 4 anemia and lymphopenia Gr 3 thrombocytopenia |
|
Younes et al. [36] | Panobinostat | II | 129 | NR | DCR 74% CR 5 PR 30 | PFS 6.1 months | Gr 3-4 anemia, neutropenia, and thrombocytopenia |
|
Johnston et al. [38] | Everolimus | II | 19 | 84% | ORR 47% CR 1 PR 8 | TTP 7.2 months | Gr >3 pulmonary toxicity |
|
Fehniger et al. [39] | Lenalidomide | II | 36 | 87% | ORR 19% CR 1 PR 6 | NR | Gr 3-4 anemia and neutropenia thrombocytopenia |
|
Georgakis et al. [40] | Tipifarnib | II | 19 | NR | ORR 21% CR 2 PR 2 | TTP 3.6 months OR 14.8 months | Gr 3-4 anemia, neutropenia, thrombocytopenia, and fatigue |
|